¿ Aronex Pharmaceuticals Inc., of The Woodlands, Texas, began a Phase II study evaluating the chemotherapeutic agent Platar in metastatic renal-cell carcinoma.
¿ Enzon Inc., of Piscataway, N.J., filed an investigational new drug application with the FDA for PEG-Camptothecin (Prothecan), a pro-drug form of the topoisomerase 1 inhibitor camptothecin, which is known to be an efficacious oncolytic agent. Enzon has been able to overcome the drug¿s significant delivery problems in animal studies.
¿ Exelixis Pharmaceuticals Inc., of South San Francisco, achieved the first of two milestones in its collaboration with Bayer AG, of Leverkusen, Germany, covering the identification of targets and formatting of high-throughput assays for the development of new generations of crop-protection agents. The milestone triggered an undisclosed payment.
¿ ImmuLogic Pharmaceutical Corp., of Waltham, Mass., said its board voted to liquidate and dissolve the company, returning $36.7 million, or $1.80 per share, to shareholders. The company said earlier it would end its business, in the wake of failed clinical trials of its allergy vaccines. (See BioWorld Today, Feb. 9, 1999, p. 1.)
¿ Nabi, of Boca Raton, Fla., said its Nabi-HB (hepatitis immune globulin B) is being shipped to customers. It was approved last month. (See BioWorld Today, March 26, 1999, p. 1.)